Clinical evaluation of a serological assay using a monoclonal antibody (TB72) to the 38 kDa antigen of Mycobacterium tuberculosis

Autor: GH Bothamley, RM Rudd

Publikováno v: The European respiratory journal. 7(2)

We examined an enzyme-linked immunosorbent assay (ELISA) modification of a radioimmunoassay, using the TB72 monoclonal antibody, as a serological test for tuberculosis in a clinical setting. Sera were obtained from 238 patients with suspected pulmona

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d29a20d9cd15537bd4768ee766a9a6d
https://pubmed.ncbi.nlm.nih.gov/7512931

Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.

Autor: Szlosarek PW; Center for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Center, London, England2Barts Health NHS Trust, St Bartholomew's Hospital, London, England., Steele JP; Barts Health NHS Trust, St Bartholomew's Hospital, London, England., Nolan L; Southampton University Hospital NHS Foundation Trust, Southampton, England., Gilligan D; Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, England., Taylor P; University Hospital of South Manchester NHS Foundation Trust, Wythenshawe Hospital, Manchester, England., Spicer J; Division of Cancer Studies, King's College London, Guy's Hospital, London, England., Lind M; University of Hull, Castle Hill Hospital, Cottingham, England., Mitra S; Brighton and Sussex University Hospitals, Brighton, England., Shamash J; Barts Health NHS Trust, St Bartholomew's Hospital, London, England., Phillips MM; Center for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Center, London, England2Barts Health NHS Trust, St Bartholomew's Hospital, London, England., Luong P; Center for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Center, London, England., Payne S; Barts Health NHS Trust, St Bartholomew's Hospital, London, England., Hillman P; Barts Health NHS Trust, St Bartholomew's Hospital, London, England., Ellis S; Barts Health NHS Trust, St Bartholomew's Hospital, London, England., Szyszko T; King's College London, St Thomas' Hospital, London, England., Dancey G; Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, England., Butcher L; University College London Cancer Institute, University College London, London, England., Beck S; University College London Cancer Institute, University College London, London, England., Avril NE; Cleveland Clinic, Cleveland, Ohio., Thomson J; Polaris Pharmaceuticals Inc, San Diego, California., Johnston A; Polaris Pharmaceuticals Inc, San Diego, California., Tomsa M; Center for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, John Vane Science Center, London, England., Lawrence C; Center for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, John Vane Science Center, London, England., Schmid P; Barts Health NHS Trust, St Bartholomew's Hospital, London, England14Center for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, John Vane Science Center, London, England., Crook T; Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, England., Wu BW; Polaris Pharmaceuticals Inc, San Diego, California., Bomalaski JS; Polaris Pharmaceuticals Inc, San Diego, California., Lemoine N; Center for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Center, London, England., Sheaff MT; Barts Health NHS Trust, St Bartholomew's Hospital, London, England., Rudd RM; Barts Health NHS Trust, St Bartholomew's Hospital, London, England., Fennell D; University of Leicester, Leicester Royal Infirmary, Leicester, England., Hackshaw A; Cancer Research UK and UCL Cancer Trials Center, University College London, London, England.

Publikováno v: JAMA oncology [JAMA Oncol] 2017 Jan 01; Vol. 3 (1), pp. 58-66.

Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.

Autor: Rossi A; S.G. Moscati Hospital, Avellino, Città Ospedaliera, Contrada Amoretta, Avellino, Italy. arossi_it@yahoo.it, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee SM

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2012 May 10; Vol. 30 (14), pp. 1692-8. Date of Electronic Publication: 2012 Apr 02.

Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.

Autor: Lee SM; Department of Oncology, University College Hospital, London, UK. sm.lee@uclh.nhs.uk, James LE, Qian W, Spiro S, Eisen T, Gower NH, Ferry DR, Gilligan D, Harper PG, Prendiville J, Hocking M, Rudd RM

Publikováno v: Thorax [Thorax] 2009 Jan; Vol. 64 (1), pp. 75-80. Date of Electronic Publication: 2008 Sep 11.

Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.

Autor: Fennell DA; Department of Medical Oncology, St Bartholomew's Hospital, London, United Kingdom., Steele JP, Shamash J, Slater SE, Sheaff MT, Wells P, Rudd RM, Stebbing J

Publikováno v: International journal of cancer [Int J Cancer] 2007 Dec 01; Vol. 121 (11), pp. 2575-7.